Compare NBIX & IESC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBIX | IESC |
|---|---|---|
| Founded | 1992 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Engineering & Construction |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.5B | 12.7B |
| IPO Year | 1996 | 1997 |
| Metric | NBIX | IESC |
|---|---|---|
| Price | $166.05 | $169.07 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 29 | 0 |
| Target Price | ★ $207.50 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 421.1K |
| Earning Date | 11-02-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 41.95 | ★ 51.87 |
| EPS | 5.26 | ★ 17.52 |
| Revenue | $161,626,000.00 | ★ $3,371,468,000.00 |
| Revenue This Year | $36.46 | $25.64 |
| Revenue Next Year | $17.43 | $48.14 |
| P/E Ratio | $31.49 | ★ $11.53 |
| Revenue Growth | ★ 977.51 | 16.89 |
| 52 Week Low | $122.14 | $194.32 |
| 52 Week High | $186.12 | $816.51 |
| Indicator | NBIX | IESC |
|---|---|---|
| Relative Strength Index (RSI) | 76.47 | 24.94 |
| Support Level | $152.67 | N/A |
| Resistance Level | $169.57 | $349.66 |
| Average True Range (ATR) | 3.61 | 13.78 |
| MACD | 2.23 | 0.59 |
| Stochastic Oscillator | 86.44 | 12.74 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
IES Holdings Inc owns and manages subsidiaries that design and installs integrated electrical and technology systems and provide infrastructure products and services. It has four business segments; Communications, Residential, Infrastructure Solutions, and Commercial & Industrial. The majority of the revenue for the company is generated from its Residential segment in which the company provides electrical installation services for single-family housing and multi-family apartment complexes, as well as heating, ventilation, and air conditioning (HVAC) and plumbing installation services. This segment also provides services for installing residential solar power, both for new construction and existing residences.